ALK-001

DRUG3 trials

Sponsors

Alkeus Pharmaceuticals, Inc.

Conditions

Autosomal Recessive Stargardt Disease 1 (ABCA4-related)Stargardt DiseaseStargardt Macular DegenerationStargardt Macular Dystrophy

Phase 2

Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease

Enrolling by invitationNCT02402660

Alkeus Pharmaceuticals, Inc.Autosomal Recessive Stargardt Disease 1 (ABCA4-related), Stargardt Disease, Stargardt Macular Degeneration +1

Start: 2015-08-31End: 2026-11-30Target: 160Updated: 2025-04-27

Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)

Active, not recruitingNCT04239625

Alkeus Pharmaceuticals, Inc.Autosomal Recessive Stargardt Disease 1 (ABCA4-related), Stargardt Disease, Stargardt Macular Degeneration +1

Start: 2019-12-20End: 2026-12-31Target: 200Updated: 2025-04-27

Phase 3

Study of ALK-001 on the Progression of Stargardt Disease

RecruitingNCT07419334

Alkeus Pharmaceuticals, Inc.Stargardt Disease

Start: 2026-06-03End: 2030-12-01Target: 230Updated: 2026-09-18

Related Papers

Safety and Effects of Gildeuretinol Acetate on Retinal Atrophic Lesions in Stargardt Disease

JAMA Ophthalmology2026-09-03

Test-Retest Variability of Functional and Structural Parameters in Patients with Stargardt Disease Participating in the SAR422459 Gene Therapy Trial.

2016-10-0135 citations